Sphingosine kinase inhibitors
US8557800B2 · kind B2 · utility
10Cited by
9References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 19, 2011 |
| Grant date | Oct 15, 2013 |
| Priority date | — |
| Expiry date | Dec 1, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/74
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.